CEO Will Discuss Key Strengths and Progress, Announce New Developments

BETHESDA, Md., March 19, 2013 — Northwest
Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company
developing DCVax® personalized immune therapies for solid tumor
cancers, announced today that Linda F. Powers, the Company’s
Chairman and Chief Executive Officer, will be presenting at the
25th Annual ROTH Conference at 8:30 a.m. PDT on Wednesday, March
20, 2013, at the Ritz-Carlton, Laguna Niguel, Dana Point,
California.

Ms. Powers’ presentation will discuss the Company’s lead Phase
III trial with DCVax-L for brain cancer, including guidance on
enrollment, progress in Europe, and anticipated timelines for major
milestones.  Ms. Powers will also discuss the Company’s
pending Phase I/II trial with DCVax-Direct for all solid tumor
cancers that are inoperable, which is preparing to launch in
Q2.  Ms. Powers will comment on the Company’s key strengths
and differentiation in the immune therapy space, and will announce
certain new developments.

The presentation will take place in Track 8 of the conference,
in The Promenade – White Room, and will be available by web cast at
http://wsw.com/webcast/roth27/nwbo/.  The webcast will
remain available for 90 days following the presentation.
 It will also be available on the NW Bio Website
starting on Thursday, March 21, 2013, at www.nwbio.com.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both the
United States and Europe.  The Company has a broad platform
technology for DCVax® dendritic cell-based vaccines.  The
Company’s lead program is a 312-patient Phase III trial in newly
diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive
and lethal brain cancer.  The Company also previously received
clearance from the FDA for a 612-patient Phase III trial in
prostate cancer, and clearance from the FDA for Phase I/II trials
in multiple other cancers.  The Company has also conducted a
Phase I/II trial with DCVax® for metastatic ovarian cancer together
with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax® and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995.  Words such as “expect,” “believe,”
“intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and
similar expressions are intended to identify forward-looking
statements.  Actual results may differ materially from those
projected in any forward-looking statement.  Specifically,
there are a number of important factors that could cause actual
results to differ materially from those anticipated, such as the
Company’s ability to raise additional capital, risks related to the
Company’s ability to enroll patients in its clinical trials and
complete the trials on a timely basis, the uncertainty of the
clinical trials process, uncertainties about the timely performance
of third parties, and whether the Company’s products will
demonstrate safety and efficacy.  Additional information on
these and other factors, including Risk Factors, which could affect
the Company’s results, is included in its Securities and Exchange
Commission (“SEC”) filings.  Finally, there may be other
factors not mentioned above or included in the Company’s SEC
filings that may cause actual results to differ materially from
those projected in any forward-looking statement.  You should
not place undue reliance on any forward-looking statements.
The Company assumes no obligation to update any forward-looking
statements as a result of new information, future events or
developments, except as required by securities laws.